Welcome!

Agile Computing Authors: Elizabeth White, Liz McMillan, John Basso, Kevin Benedict, Dana Gardner

News Feed Item

Express Scripts Reports Fourth Quarter and Full Year Results

Provides Initial 2013 Earnings Guidance

ST. LOUIS, Feb. 18, 2013 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) announced 2012 fourth quarter and full year net income attributable to Express Scripts shareholders from continuing operations of $515.9 million and $1,340.5 million, or $0.62 and $1.79 per diluted share, respectively. Adjusted earnings per share attributable to Express Scripts from continuing operations, as detailed in Table 4 were $1.05 and $3.74 per diluted share for the fourth quarter and full year, respectively.

"2012 was a monumental year for Express Scripts as we closed the acquisition of Medco and made significant progress integrating the two companies," stated George Paz, chairman and chief executive officer. "Our financial performance in 2012 was strong, and as we look to the future, we are well positioned to capitalize on the complementary strengths of the combined organization, which enhance our ability to improve health outcomes, lower health care costs and continue to deliver long-term growth."

Fourth Quarter 2012 Review (Results from continuing operations on an adjusted basis where indicated. See Tables 2 and 3)

All key metrics compared to 2011 were affected by the inclusion of Medco results beginning in the second quarter of 2012. Gross profit margin and EBITDA per adjusted claim increases over last year are mainly attributed to improved operating performance, increased generic utilization and realization of synergies.

  • Adjusted claims of 410.8 million, up 111%
  • Gross profit of $2.3 billion, up 160%
  • EBITDA of $1.6 billion, up 131%
  • EBITDA per adjusted claim of $4.01, up 10%
  • Cash flow from operations of $2.6 billion, compared to $0.5 billion in the fourth quarter of 2011

Full Year 2012 Review (Results from continuing operations on an adjusted basis where indicated. See Tables 2 and 3)

  • Adjusted claims of 1,395.7 million, up 86%
  • Gross profit of $7.5 billion, up 123%
  • EBITDA of $5.4 billion, up 103%
  • EBITDA per adjusted claim of $3.87, up 9%
  • Cash flow from operations of $4.8 billion, including merger-related costs, up from $2.2 billion in 2011

Due to the Federal Holiday on February 18, 2013, the Company expects to file its Annual Report on Form 10-K for the year ended December 31, 2012 with the Securities and Exchange Commission ("SEC") on Tuesday, February 19, 2013. However, in connection with this earnings release, the contents of the Form 10-K substantially in the form expected to be filed on Tuesday, February 19, 2013, are expected to be made available to the public on the "Investor Information" section of the Company's website at approximately 4:00 pm Eastern Time (3:00 p.m. Central Time) on Monday, February 18, 2013 at www.express-scripts.com/corporate. The Form 10-K, as filed with the SEC, will replace that document on the Company's website as soon as practicable following its filing with the SEC.

2013 Guidance

The Company expects to achieve adjusted earnings per diluted share from continuing operations for 2013 in the range of $4.20 to $4.30, or 12% to 15% growth over 2012. Adjusted earnings per share for 2013 exclude items as detailed in Table 6.

  • Total adjusted claims are expected to grow 5% to 7% from 1,395.7 million adjusted claims reported in 2012
  • Selling, general and administrative expense is expected to decline 8% to 10% from $2,365.9 million reported on an adjusted basis in 2012
  • EBITDA per adjusted claim is expected to grow 15% to 18% from $3.87 reported on an adjusted basis in 2012
  • Effective tax rate is expected to be approximately 39%
  • Diluted shares outstanding is expected to be in a range of 825 million to 835 million

About Express Scripts

Express Scripts (NASDAQ: ESRX) manages more than a billion prescriptions each year for tens of millions of patients. On behalf of our clients – employers, health plans, unions and government health programs – we make the use of prescription drugs safer and more affordable. Express Scripts uniquely combines three capabilities – behavioral sciences, clinical specialization and actionable data – to create Health Decision Science(SM), our innovative approach to help individuals make the best drug choices, pharmacy choices and health choices. Better decisions mean healthier outcomes.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-K filed with the SEC on or about February 19, 2013. A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Statement of Operations










Three Months Ended

December 31,


Year Ended

December 31,

(in millions, except per share data)

2012


2011


2012


2011









Revenues(*)

$ 27,410.7


$ 12,101.4


$ 93,858.1


$ 46,128.3

Cost of revenues(*)

25,107.8


11,256.9


86,527.9


42,918.4

   Gross profit

2,302.9


844.5


7,330.2


3,209.9

Selling, general and administrative

1,398.4


268.0


4,545.7


895.5

Operating income

904.5


576.5


2,784.5


2,314.4

Other (expense) income:








   Equity income from joint venture

5.5


-


14.9


-

   Interest income

4.6


4.6


10.6


12.4

   Interest expense and other

(157.4)


(115.4)


(619.0)


(299.7)


(147.3)


(110.8)


(593.5)


(287.3)

Income before income taxes

757.2


465.7


2,191.0


2,027.1

Provision for income taxes

234.4


173.7


833.3


748.6

Net income from continuing operations

522.8


292.0


1,357.7


1,278.5

Net loss from discontinued operations, net of tax

(11.8)


-


(27.6)


-

Net income

511.0


292.0


1,330.1


1,278.5

Less: Net income attributable to non-controlling interest

6.9


1.6


17.2


2.7

Net income attributable to Express Scripts

$ 504.1


$ 290.4


$ 1,312.9


$ 1,275.8









Weighted average number of common shares outstanding during the period:















   Basic

817.3


485.3


731.3


500.9

   Diluted

832.4


489.0


747.3


505.0









Basic earnings (loss) per share








   Continuing operations attributable to Express Scripts

$ 0.63


$ 0.60


$ 1.83


$ 2.55

   Discontinued operations attributable to Express Scripts

(0.01)


-


(0.04)


-

   Net earnings attributable to Express Scripts

0.62


0.60


1.80


2.55









Diluted earnings (loss) per share








   Continuing operations attributable to Express Scripts

$ 0.62


$ 0.59


$ 1.79


$ 2.53

   Discontinued operations attributable to Express Scripts

(0.01)


-


(0.04)


-

   Net earnings attributable to Express Scripts

0.61


0.59


1.76


2.53









Amounts attributable to Express Scripts shareholders:








   Income from continuing operations, net of tax

$ 515.9


$ 290.4


$ 1,340.5


$ 1,275.8

   Discontinued operations, net of tax

(11.8)


-


(27.6)


-

   Net income attributable to Express Scripts shareholders

$ 504.1


$ 290.4


$ 1,312.9


$ 1,275.8









(*) Includes retail pharmacy co-payments of $3,304.0 million and $1,412.6 million for the three months ended December 31, 2012 and 2011, respectively and $11,668.6 million and $5,786.6 million for the year ended December 31, 2012 and 2011, respectively.

EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Balance Sheet






December 31,


December 31,

(in millions)

2012


2011

Assets




Current assets:




Cash and cash equivalents

$ 2,793.9


$ 5,620.1

Restricted cash and investments

19.6


17.8

Receivables, net

5,480.6


1,915.7

Inventories

1,661.9


374.4

Deferred taxes

408.5


45.8

Prepaid expenses and other current assets

194.4


84.2

Current assets of discontinued operations

198.0


-

Total current assets

10,756.9


8,058.0

Property and equipment, net

1,634.3


416.2

Goodwill

29,359.8


5,485.7

Other intangible assets, net

16,037.9


1,620.9

Other assets

56.6


26.2

Noncurrent assets of discontinued operations

265.7


-

Total assets

$ 58,111.2


$ 15,607.0





Liabilities and stockholders' equity




Current liabilities:




Claims and rebates payable

$ 7,440.0


$ 2,874.1

Accounts payable

2,909.1


928.1

Accrued expenses

1,630.0


656.0

Current maturities of long-term debt

934.9


999.9

Current liabilities of discontinued operations

143.4


-

Total current liabilities

13,057.4


5,458.1

Long-term debt

14,980.1


7,076.4

Deferred taxes

5,948.8


546.5

Other liabilities

692.9


50.7

Noncurrent liabilities of discontinued operations

36.3


-

Total liabilities

34,715.5


13,131.7





Stockholders' equity:




Preferred stock, 15.0 shares authorized, $0.01 par value per share;




and no shares issued and outstanding

-


-

Common stock, 2,985.0 shares authorized, $0.01 par value per share;




shares issued: 818.1 and 690.7, respectively;




shares outstanding: 818.1 and 484.6, respectively

8.2


6.9

Additional paid-in capital

21,289.7


2,438.2

Accumulated other comprehensive income

18.9


17.0

Retained earnings

2,068.2


6,645.6


23,385.0


9,107.7





Common stock in treasury at cost, zero and 206.1 shares, respectively

-


(6,634.0)

Total Express Scripts stockholders' equity

23,385.0


2,473.7

Non-controlling interest

10.7


1.6

Total stockholders' equity

23,395.7


2,475.3

Total liabilities and stockholders' equity

$ 58,111.2


$ 15,607.0

EXPRESS SCRIPTS HOLDING COMPANY

Unaudited Consolidated Statement of Cash Flows


Year Ended

December 31,

(in millions)

2012


2011





Cash flows from operating activities:




Net income

$ 1,330.1


$ 1,278.5

Net loss from discontinued operations, net of tax

27.6


-

  Net income from continuing operations

1,357.7


1,278.5

Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

1,872.6


253.4

Deferred income taxes

(390.4)


137.8

Employee stock-based compensation expense

410.0


48.8

Bad debt expense

158.8


11.6

Deferred financing fees

43.6


81.0

Other, net

(118.5)


4.5

Changes in operating assets and liabilities, net of effects of acquisition:




Receivables

325.2


(206.1)

Inventories

(515.8)


8.0

Other current and noncurrent assets

303.2


119.2

Claims and rebates payable

82.8


207.5

Accounts payable

982.2


271.4

Other current and noncurrent liabilities

240.8


(22.5)

Net cash provided by operating activities - continuing operations

4,752.2


2,193.1

Net cash provided by operating activities - discontinued operations

29.4


-

Net cash flows provided by operating activities

4,781.6


2,193.1





Cash flows from investing activities:




Acquisitions, net of cash acquired

(10,326.4)


-

Purchases of property and equipment

(160.2)


(144.4)

Purchase of short-term investments

(2.8)


(25.0)

Proceeds from sale of short-term investments

4.6


45.0

Proceeds from sale of business

61.5


-

Other

(5.8)


0.5

Net cash used in investing activities - continuing operations

(10,429.1)


(123.9)

Acquisitions, cash acquired - discontinued operations

42.8


-

Net cash used in investing activities - discontinued operations

(5.4)


-

Net cash used in investing activities

(10,391.7)


(123.9)





Cash flows from financing activities:




Proceeds from long-term debt, net of discounts

7,458.9


5,580.3

Repayment of long-term debt

(3,868.5)


(0.1)

Repayment of revolving credit line, net

(1,000.0)


-

Proceeds from accounts receivable financing facility

600.0


-

Repayment of accounts receivable financing facility

(600.0)


-

Excess tax benefit relating to employee stock-based compensation

45.3


28.3

Net proceeds from employee stock plans

326.0


32.2

Deferred financing fees

(103.2)


(91.6)

Treasury stock acquired

-


(2,515.7)

Distributions paid to non-controlling interest

(8.1)


(1.1)

Other

-


(2.9)

Net cash provided by financing activities - continuing operations

2,850.4


3,029.4

Net cash used in financing activities - discontinued operations

(26.8)


-

Net cash provided by financing activities

2,823.6


3,029.4





Effect of foreign currency translation adjustment

2.0


(2.2)





Less: cash attributable to discontinued operations

(41.7)


-





Net (decrease) increase in cash and cash equivalents

(2,826.2)


5,096.4

Cash and cash equivalents at beginning of year

5,620.1


523.7

Cash and cash equivalents at end of year

$ 2,793.9


$ 5,620.1

Table 1

Express Scripts Holding Company Unaudited Consolidated Selected Information

(in millions)










Three Months Ended

December 31,


Year Ended

December 31,


2012


2011


2012


2011

Claims Volume








Continuing operations:








Network

299.2


156.4


1,020.7


600.4

Home delivery and specialty(1)

38.3


13.6


129.1


53.4

   Total claims

337.5


170.0


1,149.8


653.8









Total adjusted claims - continuing operations(2)

410.8


194.9


1,395.7


751.5









Discontinued operations:








Home delivery and specialty(1)

1.2


-


4.9


-









Total adjusted claims - discontinued operations(2)

3.6


-


14.7


-









Depreciation and Amortization (D&A):








Revenue amortization(3)

$ 28.5


$ 28.5


$ 114.0


$ 114.0

Cost of revenues depreciation

32.0


12.3


105.3


43.5

Selling, general and administrative depreciation

58.4


14.9


178.9


55.2

Selling, general and administrative amortization

483.1


10.2


1,474.4


40.7

   Total D&A - continuing operations

$ 602.0


$ 65.9


$ 1,872.6


$ 253.4









Generic Fill Rate








Network

80.6%


75.8%


79.4%


75.3%

Home delivery

73.7%


64.7%


71.5%


63.0%

Overall

79.8%


74.8%


78.5%


74.2%









Note: See Appendix for Footnotes and Additional Notes.

    

Table 2

Calculation of Express Scripts Holding Company Adjusted Gross Profit and SG&A - Continuing Operations

(in millions)










Three Months Ended

December 31,


Year Ended

December 31,


2012


2011


2012


2011

Gross profit, as reported

$ 2,302.9


$ 844.5


$ 7,330.2


$ 3,209.9

Amortization of legacy Express Scripts intangible assets (3)

28.5


28.5


114.0


114.0

Non-recurring transaction and integration costs (4)

16.0


-


49.7


-

Accrual related to client contractual dispute (5)

-


30.0


-


30.0

Adjusted gross profit

$ 2,347.4


$ 903.0


$ 7,493.9


$ 3,353.9









Selling, general and administrative, as reported

$ 1,398.4


$ 268.0


$ 4,545.7


$ 895.5

Amortization of legacy Express Scripts intangible assets (3)

10.2


10.2


40.7


40.7

Amortization of Medco-related intangible assets (6)

472.9


-


1,433.7


-

Non-recurring transaction and integration costs (4)

130.8


42.2


705.4


62.5

Adjusted selling, general and administrative

$ 784.5


$ 215.6


$ 2,365.9


$ 792.3









Note: See Appendix for Footnotes and Additional Notes.

    



The Company is providing adjusted gross profit and adjusted selling, general and administrative expenses, in each case, excluding the impact of non-recurring charges and amortization of intangible assets (both of which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

    

Table 3

Express Scripts Holding Company EBITDA Reconciliation

(in millions, except per claim data)

The following is a reconciliation of net income from continuing operations attributable to Express Scripts to EBITDA from continuing operations attributable to Express Scripts. The Company believes net income is the most directly comparable measure calculated under U.S. GAAP.


Three Months Ended

December 31,


Year Ended

December 31,


2012


2011


2012


2011

Net income from continuing operations, attributable to Express Scripts, as reported

$ 515.9


$ 290.4


$ 1,340.5


$ 1,275.8

  Provision for income taxes

234.4


173.7


833.3


748.6

  Depreciation and amortization

602.0


65.9


1,872.6


253.4

  Interest expense, net

152.8


110.8


608.4


287.3

  Equity income from joint venture

(5.5)


-


(14.9)


-

EBITDA from continuing operations, attributable to Express Scripts, as reported

1,499.6


640.8


4,639.9


2,565.1

Non-recurring transaction and integration costs (4)

146.8


42.2


755.1


62.5

Accrual related to client contractual dispute (5)

-


30.0


-


30.0

Adjusted EBITDA from continuing operations, attributable to Express Scripts

$ 1,646.4


$ 713.0


$ 5,395.0


$ 2,657.6









Total adjusted claims - continuing operations

410.8


194.9


1,395.7


751.5









Adjusted EBITDA per adjusted claim

$ 4.01


$ 3.66


$ 3.87


$ 3.54









Note: See Appendix for Footnotes and Additional Notes.





    



The Company is providing adjusted EBITDA excluding the impact of non-recurring charges in order to compare the underlying financial performance to prior periods.


EBITDA is earnings before other income (expense), interest, taxes, depreciation and amortization, or alternatively calculated as operating income plus depreciation and amortization. EBITDA is presented because it is a widely accepted indicator of a company's ability to service indebtedness and is frequently used to evaluate a company's performance. EBITDA, however, should not be considered as an alternative to net income, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with accounting principles generally accepted in the United States. In addition, our definition and calculation of EBITDA may not be comparable to that used by other companies.


Adjusted EBITDA per adjusted claim is a supplemental measurement used by analysts and investors to help evaluate overall operating performance. We have calculated adjusted EBITDA excluding certain charges recorded each year, as these charges are not considered an indicator of ongoing company performance. Adjusted EBITDA per adjusted claim is calculated by dividing adjusted EBITDA by the adjusted claim volume for the period. This measure is used as an indicator of EBITDA performance on a per-unit basis. Adjusted EBITDA, and as a result, adjusted EBITDA per adjusted claim, are affected by the changes in claim volumes between retail and mail-order, the relative representation of brand-name, generic and specialty pharmacy drugs, as well as the level of efficiency in the business.

    

Table 4

Calculation of Express Scripts Holding Company Adjusted EPS










Three Months Ended

December 31,


Year Ended

December 31,


2012


2011


2012


2011




(per diluted share)



EPS from continuing operations attributable to Express Scripts, as reported

$ 0.62


$ 0.59


$ 1.79


$ 2.53









Non-recurring/transaction-related items:








Transaction and integration costs (4)

0.11


0.06


0.61


0.08

Medco acquisition pre-close financing costs (7)

-


0.08


0.07


0.13

Discrete tax items (8)

(0.06)


-


(0.01)


-

Accrual related to client contractual dispute (5)

-


0.04


-


0.04









Amortization of:








Legacy Express Scripts intangible assets(3)

0.03


0.05


0.12


0.19

Medco-related intangible assets(6)

0.35


-


1.16


-









EPS from continuing operations, adjusted

$ 1.05


$ 0.82


$ 3.74


$ 2.97









EPS from discontinued operations attributable to Express Scripts, as reported

$ (0.01)


$ -


$ (0.04)


$ -









Non-recurring/transaction-related items:








Transaction and integration costs (9)

-


-


0.01


-









Amortization of:








Medco-related intangible assets(9)

-


-


0.02


-









EPS from discontinued operations, adjusted

$ (0.01)


$ -


$ (0.01)


$ -









Total EPS attributable to Express Scripts, adjusted

$ 1.04


$ 0.82


$ 3.73


$ 2.97









Note: See Appendix for Footnotes and Additional Notes.









The Company is providing EPS and EPS excluding the impact of non-recurring / transaction-related items and amortization of intangible assets (which is a non-GAAP financial measure) in order to compare the underlying financial performance to prior periods.










Table 5

Calculation of Express Scripts Holding Company Adjusted Effective Income Tax Rate

(in millions)


Year Ended

December 31, 2012




Pre-Tax


Provision for Income Taxes


Adjusted Effective Income Tax Rate



Income from continuing operations, as reported

2,191.0


833.3





Income from discontinued operations, as reported

(15.4)


12.2






2,175.6


845.5





Non-controlling interest

(17.2)


-





Total operations attributable to Express Scripts

2,158.4


845.5





Discrete tax items(8)

-


8.2





Total operations attributable to Express Scripts

2,158.4


853.7


39.6%











Note: See Appendix for Footnotes and Additional Notes.









The Company is providing adjusted effective income tax rate excluding the impact of discrete tax items (which is a non-GAAP financial measure) in order to compare the underlying financial performance to prior periods.

         


Table 6

2013 Guidance Information


Estimated

Year Ended

December 31, 2013


(per diluted share)





Adjusted EPS from continuing operations guidance

$ 4.20

to

$ 4.30





GAAP items not included in guidance:








Amortization of legacy Express Scripts intangible assets

$0.11



Amortization of Medco-related intangible assets (10)

$1.38





Transaction, integration and other non-recurring costs(11)

To be determined





Note: See Appendix for Footnotes and Additional Notes.


The full-year impact of Medco-related transaction and integration costs have yet to be determined. Accordingly, the Company is unable to include these charges in the list of GAAP items not included in guidance for 2013 revised adjusted EPS from continuing operations or to provide a reconciliation to the corresponding GAAP measure.

Appendix

Footnotes


(1) Includes home delivery, specialty and other including: (a) drugs distributed through patient assistance programs (b) drugs we distribute to other PBMs' clients under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims.


(2) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims.


(3) Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense. Revenue amortization is related to the customer contract with WellPoint which consummated upon closing of the NextRx acquisition in 2009. Under U.S. GAAP standards, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues. Intangible amortization of $28.5 million ($17.1 million and $17.9 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the three months ended December 31, 2012 and 2011. Intangible amortization of $114.0 million ($68.8 million and $71.9 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the year ended December 31, 2012 and 2011.

 

In addition, intangible amortization of $10.2 million ($6.1 million and $6.4 million net of tax in 2012 and 2011, respectively) is included in selling, general and administrative expense in the three months ended December 31, 2012 and 2011. Intangible amortization of $40.7 million ($24.5 million and $25.7 million net of tax in 2012 and 2011, respectively) is included in selling, general and administrative expense in the year ended December 31, 2012 and 2011.


(4) Non-recurring transaction and integration costs include those directly related to the acquisition of Medco Health Solutions, Inc. ("Medco").

 

Costs of $16.0 million ($10.4 million net of tax) and $49.7 million ($30.0 million net of tax) for the three months and year ended December 31, 2012, respectively, primarily composed of integration-related activities, are included in cost of revenues.

 

Costs of $131.3 million ($85.0 million net of tax) and $42.2 million ($26.4 million net of tax) primarily composed of severance costs, including stock compensation, are included in selling, general and administrative expense in the three months ended December 31, 2012 and 2011, respectively. Costs of $697.2 million ($420.7 million net of tax) and $62.5 million ($39.4 million net of tax) are included in selling, general and administrative expense in the years ended December 31, 2012 and 2011, respectively.

 

The Company recorded a net benefit of $0.5 million ($0.4 million net of tax) and net charges of $8.2 million ($4.9 million net of tax) within selling, general and administrative expenses for the three months and year ended December 31, 2012, respectively, in conjunction with the strategic decision to exit various businesses.


(5) In December 2011, the Company recorded an accrual of $30 million ($18.9 million net of tax) as an offset to revenues for the year ended December 31, 2011 related to a client contractual dispute.


(6) Amortization of intangible assets related to the acquisition of Medco of $472.9 million ($289.6 million net of tax) and $1,433.7 million ($865.2 million net of tax) for the three months and year ended December 31, 2012, respectively is included in selling, general and administrative expense.


(7) Financing costs include fees related to the amortization of remaining bridge loan fees, commitment fees related to the new credit agreement and interest and fees on the senior notes secured in conjunction with the acquisition of Medco. Costs of $63.1 million ($39.5 million net of tax) is included in interest expense in the three months ended December 31, 2011. Costs of $85.2 million ($52.3 million net of tax) and $105.0 million ($66.2 million net of tax) is included in interest expense for the years ended December 31, 2012 and 2011, respectively.


(8) Provision for income taxes includes discrete tax benefits of $51.7 million and $8.2 million for the quarter and year ended December 31, 2012, respectively. These items primarily relate to adjustments to prior year income tax return filings partially offset by a reversal of the deferred tax asset previously established for transaction-related costs that became nondeductible upon the consummation of the Merger.


(9) Net income from discontinued operations, net of tax includes $8.1 million ($5.0 million net of tax) and $25.1 million ($15.2 million net of tax) of amortization of intangible assets related to the acquisition of Medco for the three months and year ended December 31, 2012, respectively.

 

In addition, net income from discontinued operations, net of tax for the three months and year ended December 31, 2012, respectively includes a benefit of $3.7 million ($2.3 million net of tax) and charges of $7.8 million ($4.8 million net of charges) in conjunction with the strategic decision to exit various businesses.


(10) Adjusted EPS will exclude amortization of intangible assets. The current estimate of full year amortization based on the preliminary purchase price allocation for the Medco transaction. The preliminary purchase price allocation may be subject to further refinement and may result in significant changes.


(11) Adjusted EPS will exclude Medco-related transaction, integration and other non-recurring costs, including premium on early retirement of debt. The full-year impact of these costs have yet to be determined.

Appendix

Additional Notes


The Company now recognizes net income attributable to non-controlling interest which represents the share of net income allocated to members in consolidated affiliates. This share of net income was previously included within selling, general and administrative costs on the consolidated statement of operations. This classification impacted all quarters in 2012 and the third and fourth quarters of 2011 and did not impact net income attributable to Express Scripts shareholders.

 

During the fourth quarter of 2012, the Company determined that portions of the business within the Other Business Operations segment were not core to future operations and committed to a plan to dispose of these businesses. Consequently, results for the year ended December 31, 2012 have been adjusted for the discontinued operations of these businesses. This adjustment for discontinued operations impacts the second, third and fourth quarters of 2012.


Consult the Investor Information section of the Express Scripts website for the 2012 Express Scripts Recast worksheet, a document that recasts historical information reflecting these changes as www.express-scripts.com/corporate

SOURCE Express Scripts Holding Company

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
A critical component of any IoT project is the back-end systems that capture data from remote IoT devices and structure it in a way to answer useful questions. Traditional data warehouse and analytical systems are mature technologies that can be used to handle large data sets, but they are not well suited to many IoT-scale products and the need for real-time insights. At Fuze, we have developed a backend platform as part of our mobility-oriented cloud service that uses Big Data-based approache...
trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vice president of product management, IoT solutions at GlobalSign, will teach IoT developers how t...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
The demand for organizations to expand their infrastructure to multiple IT environments like the cloud, on-premise, mobile, bring your own device (BYOD) and the Internet of Things (IoT) continues to grow. As this hybrid infrastructure increases, the challenge to monitor the security of these systems increases in volume and complexity. In his session at 18th Cloud Expo, Stephen Coty, Chief Security Evangelist at Alert Logic, will show how properly configured and managed security architecture can...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.